Supplemental Figure 3B from Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Year: 2023
Type: supplementary-materials
Abstract: Relationship between veliparib exposure-% CFB in PAR levels in PBMC (A) and �B in PAR levels-ORR (B)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361930601